Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of the Safety and Immunogenicity of AdCOVID Administered as One or Two Doses
Sponsor: Altimmune, Inc.
Listed as NCT04679909, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Altimmune, Inc., it has been updated 8 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Altimmune, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .